Cilastatin

Cilastatin is a renal dehydropeptidase-I inhibitor combined with imipenem to prevent its renal tubular hydrolysis and nephrotoxic metabolite formation, ensuring adequate therapeutic levels of imipenem reach systemic circulation. Simson Pharma's Cilastatin reference standard and impurities support QC for the imipenem-cilastatin fixed-dose combination antibiotic.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Cilastatin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.

Pharmaceutical Reference Standards / Impurity Standards

Cilastatin Sodium
Cilastatin
Cilastatin EP Impurity D
Cilastatin Ammonium Salt
Cilastatin EP Impurity A
Cilastatin EP Impurity C
Cilastatin EP Impurity H
Cilastatin EP Impurity F
Cilastatin EP Impurity B
7-Chloro-2-(2,3-dimethylbut-3-enamido)hept-2-enoic Acid
Cilastatin Sodium EP Impurity E